WO2011028938A8 - Methods for lowering serum cholesterol in a subject using inhibition of pcsk9 - Google Patents

Methods for lowering serum cholesterol in a subject using inhibition of pcsk9 Download PDF

Info

Publication number
WO2011028938A8
WO2011028938A8 PCT/US2010/047726 US2010047726W WO2011028938A8 WO 2011028938 A8 WO2011028938 A8 WO 2011028938A8 US 2010047726 W US2010047726 W US 2010047726W WO 2011028938 A8 WO2011028938 A8 WO 2011028938A8
Authority
WO
WIPO (PCT)
Prior art keywords
pcsk9
serum cholesterol
methods
inhibition
subject
Prior art date
Application number
PCT/US2010/047726
Other languages
French (fr)
Other versions
WO2011028938A1 (en
Inventor
Jason Rhodes
Original Assignee
Alnylam Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals, Inc. filed Critical Alnylam Pharmaceuticals, Inc.
Publication of WO2011028938A1 publication Critical patent/WO2011028938A1/en
Publication of WO2011028938A8 publication Critical patent/WO2011028938A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to a method of lowering serum cholesterol using a double- stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene) and an antigen binding protein (ABP) that binds to and inhibits a PCSK9 protein. Also provided are methods of treating or preventing conditions associated with elevated serum cholesterol using the dsRNAs and ABPs of the invention.
PCT/US2010/047726 2009-09-02 2010-09-02 Methods for lowering serum cholestrol in a subject using inhibition of pcsk9 WO2011028938A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23937809P 2009-09-02 2009-09-02
US61/239,378 2009-09-02

Publications (2)

Publication Number Publication Date
WO2011028938A1 WO2011028938A1 (en) 2011-03-10
WO2011028938A8 true WO2011028938A8 (en) 2011-06-30

Family

ID=43649648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/047726 WO2011028938A1 (en) 2009-09-02 2010-09-02 Methods for lowering serum cholestrol in a subject using inhibition of pcsk9

Country Status (1)

Country Link
WO (1) WO2011028938A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (en) 2008-12-15 2020-08-27 Regeneron Pharma High Affinity Human Antibodies to PCSK9
WO2010147992A1 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Methods for increasing efficacy of lipid formulated sirna
US9187746B2 (en) 2009-09-22 2015-11-17 Alnylam Pharmaceuticals, Inc. Dual targeting siRNA agents
SG192118A1 (en) 2011-01-28 2013-09-30 Sanofi Sa Pharmaceutical compositions comprising human antibodies to pcsk9
AR088782A1 (en) * 2011-04-29 2014-07-10 Sanofi Sa TEST SYSTEMS AND METHODS TO IDENTIFY AND CHARACTERIZE HYPOLIPEMIATING PHARMACOS
JOP20200043A1 (en) * 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
AR087305A1 (en) 2011-07-28 2014-03-12 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT
MX363642B (en) * 2011-09-16 2019-03-28 Regeneron Pharma METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9).
EA039663B1 (en) * 2012-05-03 2022-02-24 Амген Инк. Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
US8980864B2 (en) * 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2994167B1 (en) 2013-05-06 2020-05-06 Alnylam Pharmaceuticals, Inc. Dosages and methods for delivering lipid formulated nucleic acid molecules
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EP3004171B1 (en) 2013-06-07 2021-10-13 Regeneron Pharmaceuticals, Inc. Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EA201690889A1 (en) 2013-11-12 2016-11-30 Санофи Байотекнолоджи DOSING MODES FOR USING PCSK9 INHIBITORS
MX2017000527A (en) * 2014-07-14 2017-08-10 Amgen Inc Crystalline antibody formulations.
PL3169353T3 (en) 2014-07-16 2020-06-01 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
WO2017031151A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
EP3340994A1 (en) * 2015-08-25 2018-07-04 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
JP7050807B2 (en) 2017-04-13 2022-04-08 カディラ ヘルスケア リミティド New peptide-based PCSK9 vaccine
JP2021533800A (en) 2018-08-21 2021-12-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. Nucleic acid, drug compositions and complexes containing the nucleic acid, and their use
CN111655297A (en) 2018-09-30 2020-09-11 苏州瑞博生物技术有限公司 siRNA conjugate and preparation method and application thereof
US20230313195A1 (en) * 2019-05-22 2023-10-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103614375A (en) * 2006-05-11 2014-03-05 阿尔尼拉姆医药品有限公司 Composition and method for inhibiting expression of PCSK9 gene
JOP20080381B1 (en) * 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)

Also Published As

Publication number Publication date
WO2011028938A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2011028938A8 (en) Methods for lowering serum cholesterol in a subject using inhibition of pcsk9
AU2018256633A1 (en) Therapy for enteric infections
WO2009134487A3 (en) Optimized methods for delivery of dsrna targeting the pcsk9 gene
WO2012177947A3 (en) Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
WO2012012443A3 (en) Modulation of dystrophia myotonica-protein kinase (dmpk) expression
WO2009129465A3 (en) Compositions and methods for inhibiting expression of xbp-1 gene
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2009126250A3 (en) Reprogramming a cell by inducing a pluripotent gene through rna interference
WO2011012309A8 (en) Muc1 antibodies
WO2008036741A3 (en) Mir-200 regulated genes and pathways as targets for therapeutic intervention
WO2009114475A3 (en) Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
WO2012005550A3 (en) Pharmaceutical composition for treating gallbladder carcinoma, and method for inhibiting growth and metastasis of gallbladder carcinoma and treating gallbladder carcinoma, using same
WO2008121604A3 (en) Compositions and methods for inhibiting expression of a gene from the ebola
WO2012138783A3 (en) Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
WO2007143086A3 (en) Delivery method
WO2013043817A8 (en) Antisense modulation of gcgr expression
ATE533838T1 (en) METHOD FOR IMPROVED INTRODUCTION OF DNA INTO BACTERIAL CELLS
WO2008044068A8 (en) Combination therapy
WO2008085797A3 (en) miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2012003470A3 (en) Antibody formulations
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
WO2012102527A3 (en) Novel use of regulatory t cell-specific surface protein lrig-1
WO2009143292A9 (en) Method of treating pneumoconiosis with oligodeoxynucleotides
WO2010054328A3 (en) Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10814517

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10814517

Country of ref document: EP

Kind code of ref document: A1